Maintenance of Tight Junction Integrity in the Absence of Vascular Dilation in the Brain of Mice Exposed to Ultra-High-Dose-Rate FLASH Irradiation.
Journal
Radiation research
ISSN: 1938-5404
Titre abrégé: Radiat Res
Pays: United States
ID NLM: 0401245
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
27
02
2020
accepted:
01
07
2020
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
9
3
2021
Statut:
ppublish
Résumé
Persistent vasculature abnormalities contribute to an altered CNS microenvironment that further compromises the integrity of the blood-brain barrier and exposes the brain to a host of neurotoxic conditions. Standard radiation therapy at conventional (CONV) dose rate elicits short-term damage to the blood-brain barrier by disrupting supportive cells, vasculature volume and tight junction proteins. While current clinical applications of cranial radiotherapy use dose fractionation to reduce normal tissue damage, these treatments still cause significant complications. While dose escalation enhances treatment of radiation-resistant tumors, methods to subvert normal tissue damage are clearly needed. In this regard, we have recently developed a new modality of irradiation based on the use of ultra-high-dose-rate FLASH that does not induce the classical pathogenic patterns caused by CONV irradiation. In previous work, we optimized the physical parameters required to minimize normal brain toxicity (i.e., FLASH, instantaneous intra-pulse dose rate, 6.9 · 106 Gy/s, at a mean dose rate of 2,500 Gy/s), which we then used in the current study to determine the effect of FLASH on the integrity of the vasculature and the blood-brain barrier. Both early (24 h, one week) and late (one month) timepoints postirradiation were investigated using C57Bl/6J female mice exposed to whole-brain irradiation delivered in single doses of 25 Gy and 10 Gy, respectively, using CONV (0.09 Gy/s) or FLASH (>106 Gy/s). While the majority of changes found one day postirradiation were minimal, FLASH was found to reduce levels of apoptosis in the neurogenic regions of the brain at this time. At one week and one month postirradiation, CONV was found to induce vascular dilation, a well described sign of vascular alteration, while FLASH minimized these effects. These results were positively correlated with and temporally coincident to changes in the immunostaining of the vasodilator eNOS colocalized to the vasculature, suggestive of possible dysregulation in blood flow at these latter times. Overall expression of the tight junction proteins, occludin and claudin-5, which was significantly reduced after CONV irradiation, remained unchanged in the FLASH-irradiated brains at one and four weeks postirradiation. Our data further confirm that, compared to isodoses of CONV irradiation known to elicit detrimental effects, FLASH does not damage the normal vasculature. These data now provide the first evidence that FLASH preserves microvasculature integrity in the brain, which may prove beneficial to cognition while allowing for better tumor control in the clinic.
Identifiants
pubmed: 33348373
pii: 441604
doi: 10.1667/RADE-20-00060.1
pmc: PMC7773228
mid: NIHMS1657029
doi:
Substances chimiques
Nitric Oxide Synthase Type III
EC 1.14.13.39
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-635Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001416
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA244091
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS089575
Pays : United States
Informations de copyright
©2020 by Radiation Research Society. All rights of reproduction in any form reserved.
Références
Med Phys. 2017 Mar;44(3):1157-1167
pubmed: 28094853
Neuro Oncol. 2018 Jan 10;20(1):132-142
pubmed: 29016809
Med Phys. 2018 Feb;45(2):863-874
pubmed: 29206287
Life Sci. 2013 Oct 17;93(17):611-6
pubmed: 23727455
Nat Commun. 2019 Nov 15;10(1):5172
pubmed: 31729378
Proc Natl Acad Sci U S A. 2019 May 28;116(22):10943-10951
pubmed: 31097580
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1002-10
pubmed: 18313524
Physiol Rev. 2013 Apr;93(2):525-69
pubmed: 23589827
Biochem Biophys Res Commun. 2015 Jan 2;456(1):541-6
pubmed: 25498542
Clin Cancer Res. 2020 Mar 15;26(6):1497-1506
pubmed: 31796518
Antioxid Redox Signal. 2015 May 10;22(14):1230-42
pubmed: 25330054
Med Phys. 2017 Feb;44(2):725-735
pubmed: 28019660
J Clin Invest. 1997 Nov 1;100(9):2146-52
pubmed: 9410890
Radiat Res. 2000 Apr;153(4):357-70
pubmed: 10798963
J Neurosurg. 2019 Mar 15;:1-9
pubmed: 30875690
Neuro Oncol. 2017 May 1;19(5):689-698
pubmed: 28039368
Curr Treat Options Oncol. 2006 Nov;7(6):517-23
pubmed: 17032563
Radiother Oncol. 2020 Mar;144:180-188
pubmed: 31835173
Radiother Oncol. 2019 Oct;139:11-17
pubmed: 31253466
Front Neurol. 2019 Mar 15;10:233
pubmed: 30930843
J Comp Neurol. 2000 Oct 2;425(4):479-94
pubmed: 10975875
Environ Mol Mutagen. 2016 Jun;57(5):341-9
pubmed: 27175611
Nat Rev Neurol. 2017 Jan;13(1):52-64
pubmed: 27982041
Sci Transl Med. 2014 Jul 16;6(245):245ra93
pubmed: 25031268
Brain Res. 2003 Apr 18;969(1-2):59-69
pubmed: 12676365
Front Oncol. 2020 Jan 17;9:1563
pubmed: 32010633
Radiother Oncol. 2018 Dec;129(3):582-588
pubmed: 30177374
Front Oncol. 2019 Nov 15;9:1259
pubmed: 31803626
J Neurosurg Pediatr. 2019 Sep 20;:1-9
pubmed: 31629322
Brain Res. 2012 Jan 18;1433:114-26
pubmed: 22153623
J Clin Invest. 2012 Jul;122(7):2454-68
pubmed: 22653056
Insights Imaging. 2018 Dec;9(6):1057-1075
pubmed: 30411280
Curr Neurol Neurosci Rep. 2019 Aug 23;19(10):73
pubmed: 31440841
Radiother Oncol. 2019 Oct;139:34-39
pubmed: 31174897
Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):37-42
pubmed: 2298633
Clin Oncol (R Coll Radiol). 2019 Jul;31(7):407-415
pubmed: 31010708
Br J Radiol. 2019 Jan;92(1093):20180008
pubmed: 29694234
Microvasc Res. 2013 Mar;86:1-10
pubmed: 23261753
Transl Stroke Res. 2020 Aug;11(4):689-699
pubmed: 31802427
J Biol Chem. 2000 Apr 21;275(16):11929-33
pubmed: 10766821
Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d
pubmed: 21890489
Radiother Oncol. 2017 Sep;124(3):365-369
pubmed: 28545957
Radiother Oncol. 2019 Jul;136:50-55
pubmed: 31015129
Ther Clin Risk Manag. 2019 Nov 18;15:1351-1367
pubmed: 31819462
Clin Cancer Res. 2019 Jan 1;25(1):35-42
pubmed: 29875213
Brain Res. 2007 Sep 26;1171:42-51
pubmed: 17761150
PLoS One. 2013 Jul 16;8(7):e68408
pubmed: 23874613
Ann Clin Transl Neurol. 2018 Dec 10;6(2):379-385
pubmed: 30847370
Neurology. 2017 Feb 21;88(8):789-796
pubmed: 28122904
Radiother Oncol. 2019 Oct;139:4-10
pubmed: 31253467
Nat Med. 2002 Sep;8(9):955-62
pubmed: 12161748